Mass­a­chu­setts judge dis­miss­es law­suit against Bio­gen over failed launch of Alzheimer's drug Aduhelm

A Mass­a­chu­setts fed­er­al judge on Wednes­day dis­missed a class ac­tion law­suit filed by in­vestors against Bio­gen and sev­er­al of its cur­rent and for­mer ex­ec­u­tives over the com­pa­ny’s failed Alzheimer’s drug, Aduhelm (ad­u­canum­ab).

The in­vestors ar­gued that Bio­gen’s con­tact with the FDA was un­law­ful and that the com­pa­ny made 25 false and mis­lead­ing state­ments, in­clud­ing state­ments about the roll­out and price of the drug.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN